Literature DB >> 10738680

Human T-cell lymphotropic virus-I in Latin America.

E Gotuzzo1, C Arango, A de Queiroz-Campos, R E Istúriz.   

Abstract

HTLV-1 infection is endemic in several Latin American countries. HTLV-1-associated myelophathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia lymphoma (ATLL) are emerging diseases in the region. Documented risk factors for acquiring the virus include breast-feeding, contaminated blood transfusion, and sexual intercourse, all of which are amenable to prevention efforts. Strongyloides stercoralis hyperinfection syndrome and therapeutic failure in apparently healthy patients with nondisseminated strongyloidiasis may be markers of HTLV-1 infection. HTLV-1 co-infection may adversely effect the clinical course of scabies and HIV disease. The new enzyme-linked immunosorbent assays (ELISA) are sensitive and specific, and Western blot technology is reliable for differentiating HTLV-1 from less common HTLV-2. HTLV-1 screening of blood donors and individuals with any disorder that suggests infection has become a necessity in Latin America to prevent the spread of this important emerging pathogen.

Entities:  

Mesh:

Year:  2000        PMID: 10738680     DOI: 10.1016/s0891-5520(05)70225-7

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  22 in total

Review 1.  Strongyloidiasis: A Neglected Tropical Disease.

Authors:  Alejandro Krolewiecki; Thomas B Nutman
Journal:  Infect Dis Clin North Am       Date:  2019-03       Impact factor: 5.982

2.  The Changing Epidemiology of Human T-Cell Lymphotropic Virus Type 1 Infection in Peruvian Female Sex Workers, 1993-2010.

Authors:  Jenell Stewart; Kristen Heitzinger; Simon Pollett; Martha Calderón; Jorge Alarcón; Thanh G N Ton; Joseph R Zunt
Journal:  Am J Trop Med Hyg       Date:  2016-11-22       Impact factor: 2.345

3.  High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in peru.

Authors:  Jorge O Alarcón; Heidi B Friedman; Silvia M Montano; Joseph R Zunt; King K Holmes; Gerald V Quinnan
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion.

Authors:  Ayse Kubra Coskun; Richard E Sutton
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.

Authors:  I Best; V Adaui; K Verdonck; E González; M Tipismana; D Clark; E Gotuzzo; G Vanham
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 6.  [Vertical transmission of HTLV-1 in Peru].

Authors:  Jorge Alarcón Villaverde; Franco Romaní Romaní; Silvia Montano Torres; Joseph R Zunt
Journal:  Rev Peru Med Exp Salud Publica       Date:  2011-03

7.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

Review 8.  Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.

Authors:  Michael Bindhu; Amrithraj Nair; Michael D Lairmore
Journal:  Front Biosci       Date:  2004-09-01

9.  High seroprevalence of human T-cell lymphotropic virus type 1 in blood donors in Guyana and molecular and phylogenetic analysis of new strains in the Guyana shelf (Guyana, Suriname, and French Guiana).

Authors:  Jean-François Pouliquen; Lynette Hardy; Anne Lavergne; Eric Kafiludine; Mirdad Kazanji
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 10.  Human infection with Strongyloides stercoralis and other related Strongyloides species.

Authors:  Thomas B Nutman
Journal:  Parasitology       Date:  2016-05-16       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.